BB Biotech AG's Form 4 filing
Molecular Templates, Inc.MTEM · filed Nov 18, 2024
- Accession no.
- 0000950170-24-128208
- Filed
- Nov 18, 2024, 9:12 PM ET
- Trade date
- Apr 2-Nov 14, 2024
- Filing delay
- 230 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market sales total $845.8K. It was filed 230 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BB Biotech AGCIK 0000924223 | 10% Owner |
| Biotech Target N VCIK 0001259870 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Common Stock | SSaleDisposed | −1,279,820 | $0.6609 | −$845,833.04 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 2, 2024 | Common Stock | PPurchaseAcquired | +134,667 | $2.35 | +$316,332.78 | 134,667 | Direct | Duplicate filing |
| Apr 2, 2024 | Common Stock | PPurchaseAcquired | +769,334 | $0.125 | +$96,166.75 | 769,334 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Molecular Templates, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.